This suggests that reprograming of PDH activity is essential for tumorigenesis of mutant IDH cells and that PDK inhibitors/PDH agonists deserve further investigation as potential therapeutic targets for low-grade gliomas. This evidence concerns the gene IDH1 and glioma.